Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany].

Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS.

Aktuelle Urol. 2019 Nov 19. doi: 10.1055/a-1018-1651. [Epub ahead of print] German.

2.

Laser fibre, rather than the stone, may harm the scope: retrospective monocentric analysis of 26 pre- and intraoperative factors of flexible ureteroscope (fURS) damage.

Ozimek T, Cordes J, Gilbert N, Hupe MC, Wiessmeyer JR, Schneider MH, Merseburger AS, Kramer MW.

World J Urol. 2019 Oct 28. doi: 10.1007/s00345-019-02988-0. [Epub ahead of print]

PMID:
31659464
3.

[Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups].

Hupe MC, Offermann A, Sailer V, Merseburger AS, Perner S.

Aktuelle Urol. 2019 Dec;50(6):619-624. doi: 10.1055/a-0918-9473. Epub 2019 Aug 7. German.

PMID:
31390661
4.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Int J Cancer. 2020 Jan 15;146(2):577-588. doi: 10.1002/ijc.32551. Epub 2019 Jul 19.

PMID:
31271443
5.

Disruption of the Extracellular Matrix Progressively Impairs Central Nervous System Vascular Maturation Downstream of β-Catenin Signaling.

Jensen LD, Hot B, Ramsköld D, Germano RFV, Yokota C, Giatrellis S, Lauschke VM, Hubmacher D, Li MX, Hupe M, Arnold TD, Sandberg R, Frisén J, Trusohamn M, Martowicz A, Wisniewska-Kruk J, Nyqvist D, Adams RH, Apte SS, Vanhollebeke B, Stenman JM, Kele J.

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1432-1447. doi: 10.1161/ATVBAHA.119.312388. Epub 2019 May 9.

6.

TRIM24 as an independent prognostic biomarker for prostate cancer.

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S.

Urol Oncol. 2019 Sep;37(9):576.e1-576.e10. doi: 10.1016/j.urolonc.2019.05.006. Epub 2019 Jun 7.

PMID:
31178279
7.

[Molecular tumor board-urothelial cancer].

Hupe MC, Gakis G, Seiler R.

Urologe A. 2019 Jul;58(7):760-767. doi: 10.1007/s00120-019-0967-5. Review. German.

PMID:
31172245
8.

The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

Offermann A, Hupe MC, Sailer V, Merseburger AS, Perner S.

World J Urol. 2019 Apr 2. doi: 10.1007/s00345-019-02744-4. [Epub ahead of print] Review.

PMID:
30941561
9.

Clinical Pharmacology: A Comprehensive Drug Reference.

Freundlich S, Hupe M.

Med Ref Serv Q. 2018 Oct-Dec;37(4):386-396. doi: 10.1080/02763869.2018.1514911. Review.

PMID:
30722769
10.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

11.

Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes.

Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS.

Front Oncol. 2018 Nov 27;8:543. doi: 10.3389/fonc.2018.00543. eCollection 2018.

12.

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).

Nicklas AP, Kramer MW, Serth J, Hennenlotter J, Hupe MC, Reimer DU, Stenzl A, Merseburger AS, Kuczyk MA, von Klot CJ.

Adv Ther. 2018 Nov;35(11):2054-2068. doi: 10.1007/s12325-018-0789-7. Epub 2018 Sep 19.

13.

Extended Techniques of Minimally Invasive Surgery in the Retroperitoneum: Practice Pattern in German Urology Departments.

Hupe MC, Kramer MW, Ozimek T, Merseburger AS, Imkamp F.

Urol Int. 2018;101(3):345-350. doi: 10.1159/000493148. Epub 2018 Sep 18.

PMID:
30227439
14.

[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society].

Hupe MC, Merseburger AS, de Wit M, Rexer H, Gschwend JE, Krege S.

Aktuelle Urol. 2018 Aug;49(4):346-354. doi: 10.1055/a-0645-1076. Epub 2018 Aug 7. German.

PMID:
30086593
15.

The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells.

Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV.

World J Urol. 2019 Feb;37(2):343-349. doi: 10.1007/s00345-018-2382-8. Epub 2018 Jun 22.

PMID:
29934670
16.

Steep Infundibulopelvic Angle as a New Risk Factor for Flexible Ureteroscope Damage and Complicated Postoperative Course.

Ozimek T, Cordes J, Wiessmeyer JR, Schneider MH, Hupe MC, Gilbert N, Merseburger AS, Kramer MW.

J Endourol. 2018 Jul;32(7):597-602. doi: 10.1089/end.2018.0147. Epub 2018 Jun 7.

PMID:
29737199
17.

Diarrhea and flatulence are major bowel disorders after radical cystectomy: Results from a cross-sectional study in bladder cancer patients.

Hupe MC, Vahlensieck W, Ozimek T, Struck JP, Hennig MJP, Tezval H, von Klot CA, Merseburger AS, Kuczyk MA, Kramer MW.

Urol Oncol. 2018 May;36(5):237.e1-237.e8. doi: 10.1016/j.urolonc.2017.12.014. Epub 2018 Feb 1.

PMID:
29395950
18.

[Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Hupe MC, Offermann A, Perabo F, Chandhasin C, Perner S, Merseburger AS, Cronauer MV.

Urologe A. 2018 Feb;57(2):148-154. doi: 10.1007/s00120-017-0541-y. Review. German.

PMID:
29147733
19.

Topical 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice.

Tiganescu A, Hupe M, Uchida Y, Mauro T, Elias PM, Holleran WM.

Endocrinology. 2018 Jan 1;159(1):547-556. doi: 10.1210/en.2017-00607.

20.

Retrospective Cost Analysis of a Single-Center Reusable Flexible Ureterorenoscopy Program: A Comparative Cost Simulation of Disposable fURS as an Alternative.

Ozimek T, Schneider MH, Hupe MC, Wiessmeyer JR, Cordes J, Chlosta PL, Merseburger AS, Kramer MW.

J Endourol. 2017 Dec;31(12):1226-1230. doi: 10.1089/end.2017.0427. Epub 2017 Nov 17.

PMID:
29073769
21.

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

22.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

23.

Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels.

Hupe M, Li MX, Kneitz S, Davydova D, Yokota C, Kele J, Hot B, Stenman JM, Gessler M.

Sci Signal. 2017 Jul 11;10(487). pii: eaag2476. doi: 10.1126/scisignal.aag2476.

PMID:
28698213
24.

[The Lubeck medical consultation bag].

Hupe MC, Hennig MJP, Struck JP, Salem J, Merseburger AS, Kramer MW.

Urologe A. 2017 May;56(5):662-664. doi: 10.1007/s00120-017-0372-x. German. No abstract available.

PMID:
28289781
25.

Defects in Stratum Corneum Desquamation Are the Predominant Effect of Impaired ABCA12 Function in a Novel Mouse Model of Harlequin Ichthyosis.

Zhang L, Ferreyros M, Feng W, Hupe M, Crumrine DA, Chen J, Elias PM, Holleran WM, Niswander L, Hohl D, Williams T, Torchia EC, Roop DR.

PLoS One. 2016 Aug 23;11(8):e0161465. doi: 10.1371/journal.pone.0161465. eCollection 2016.

27.

Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer.

Jordan AR, Lokeshwar SD, Lopez LE, Hennig M, Chipollini J, Yates T, Hupe MC, Merseburger AS, Shiedlin A, Cerwinka WH, Liu K, Lokeshwar VB.

Oncotarget. 2017 Apr 11;8(15):24262-24274. doi: 10.18632/oncotarget.10529.

28.

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.

Merseburger AS, Hupe MC.

Adv Ther. 2016 Jul;33(7):1072-93. doi: 10.1007/s12325-016-0351-4. Epub 2016 May 31. Review.

29.

[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].

Hupe MC, Kramer MW, Kuczyk MA, Merseburger AS.

Aktuelle Urol. 2015 May;46(3):242-7. doi: 10.1055/s-0035-1549948. Epub 2015 Jun 12. Review. German.

PMID:
26077309
30.

Successful Pregnancy and Neobladder Subsequent to Muscle Invasive Bladder Cancer and Fertility Preserving Surgery: Case Report and Review of the Literature.

Hupe MC, Merseburger AS, Günter HH, Wüstemann M, von Kaisenberg CS.

Urol Int. 2016;96(4):488-91. doi: 10.1159/000430921. Epub 2015 May 30. Review.

PMID:
26044131
31.

Developing proteomic biomarkers for bladder cancer: towards clinical application.

Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A.

Nat Rev Urol. 2015 Jun;12(6):317-30. doi: 10.1038/nrurol.2015.100. Epub 2015 May 26. Review.

PMID:
26032553
32.

Impact of 2004 ISUP/WHO classification on bladder cancer grading.

Lokeshwar SD, Ruiz-Cordero R, Hupe MC, Jorda M, Soloway MS.

World J Urol. 2015 Dec;33(12):1929-36. doi: 10.1007/s00345-015-1548-x. Epub 2015 Apr 2.

PMID:
25833661
33.

UVB induces epidermal 11β-hydroxysteroid dehydrogenase type 1 activity in vivo.

Tiganescu A, Hupe M, Jiang YJ, Celli A, Uchida Y, Mauro TM, Bikle DD, Elias PM, Holleran WM.

Exp Dermatol. 2015 May;24(5):370-6. doi: 10.1111/exd.12682.

34.

Preoperative and modifiable factors to lower postoperative complications after radical cystectomy.

Hupe MC, Kramer MW, Merseburger AS.

Curr Urol Rep. 2015 Apr;16(4):19. doi: 10.1007/s11934-015-0493-y. Review.

PMID:
25691438
35.

Sebaceous gland, hair shaft, and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency.

Gruber R, Sugarman JL, Crumrine D, Hupe M, Mauro TM, Mauldin EA, Thyssen JP, Brandner JM, Hennies HC, Schmuth M, Elias PM.

Am J Pathol. 2015 Apr;185(4):1012-21. doi: 10.1016/j.ajpath.2014.12.012. Epub 2015 Feb 7.

36.

Cellular basis of secondary infections and impaired desquamation in certain inherited ichthyoses.

Chan A, Godoy-Gijon E, Nuno-Gonzalez A, Crumrine D, Hupe M, Choi EH, Gruber R, Williams ML, Choate K, Fleckman PH, Elias PM.

JAMA Dermatol. 2015 Mar;151(3):285-92. doi: 10.1001/jamadermatol.2014.3369.

37.

Topical hesperidin enhances epidermal function in an aged murine model.

Man G, Mauro TM, Zhai Y, Kim PL, Cheung C, Hupe M, Crumrine D, Elias PM, Man MQ.

J Invest Dermatol. 2015 Apr;135(4):1184-1187. doi: 10.1038/jid.2014.486. Epub 2014 Nov 17. No abstract available.

38.

Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated.

Lin TK, Man MQ, Santiago JL, Scharschmidt TC, Hupe M, Martin-Ezquerra G, Youm JK, Zhai Y, Trullas C, Feingold KR, Elias PM.

J Invest Dermatol. 2014 Dec;134(12):2890-2897. doi: 10.1038/jid.2014.265. Epub 2014 Jul 3.

39.

Topical hesperidin prevents glucocorticoid-induced abnormalities in epidermal barrier function in murine skin.

Man G, Mauro TM, Kim PL, Hupe M, Zhai Y, Sun R, Crumrine D, Cheung C, Nuno-Gonzalez A, Elias PM, Man MQ.

Exp Dermatol. 2014 Sep;23(9):645-51. doi: 10.1111/exd.12480. Epub 2014 Jul 31.

40.

3D In vitro model of a functional epidermal permeability barrier from human embryonic stem cells and induced pluripotent stem cells.

Petrova A, Celli A, Jacquet L, Dafou D, Crumrine D, Hupe M, Arno M, Hobbs C, Cvoro A, Karagiannis P, Devito L, Sun R, Adame LC, Vaughan R, McGrath JA, Mauro TM, Ilic D.

Stem Cell Reports. 2014 Apr 24;2(5):675-89. doi: 10.1016/j.stemcr.2014.03.009. eCollection 2014 May 6.

41.

Lowered humidity produces human epidermal equivalents with enhanced barrier properties.

Sun R, Celli A, Crumrine D, Hupe M, Adame LC, Pennypacker SD, Park K, Uchida Y, Feingold KR, Elias PM, Ilic D, Mauro TM.

Tissue Eng Part C Methods. 2015 Jan;21(1):15-22. doi: 10.1089/ten.TEC.2014.0065.

42.

Basis for enhanced barrier function of pigmented skin.

Man MQ, Lin TK, Santiago JL, Celli A, Zhong L, Huang ZM, Roelandt T, Hupe M, Sundberg JP, Silva KA, Crumrine D, Martin-Ezquerra G, Trullas C, Sun R, Wakefield JS, Wei ML, Feingold KR, Mauro TM, Elias PM.

J Invest Dermatol. 2014 Sep;134(9):2399-2407. doi: 10.1038/jid.2014.187. Epub 2014 Apr 14.

43.

Increased glucocorticoid activation during mouse skin wound healing.

Tiganescu A, Hupe M, Uchida Y, Mauro T, Elias PM, Holleran WM.

J Endocrinol. 2014 Mar 7;221(1):51-61. doi: 10.1530/JOE-13-0420. Print 2014 Apr.

PMID:
24464022
44.

Differential expression of SDF-1 isoforms in bladder cancer.

Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB.

J Urol. 2014 Jun;191(6):1899-1905. doi: 10.1016/j.juro.2013.11.053. Epub 2013 Nov 26.

45.

cFLIP regulates skin homeostasis and protects against TNF-induced keratinocyte apoptosis.

Panayotova-Dimitrova D, Feoktistova M, Ploesser M, Kellert B, Hupe M, Horn S, Makarov R, Jensen F, Porubsky S, Schmieder A, Zenclussen AC, Marx A, Kerstan A, Geserick P, He YW, Leverkus M.

Cell Rep. 2013 Oct 31;5(2):397-408. doi: 10.1016/j.celrep.2013.09.035.

46.

Evaluation of TRAP-sequencing technology with a versatile conditional mouse model.

Hupe M, Li MX, Gertow Gillner K, Adams RH, Stenman JM.

Nucleic Acids Res. 2014 Jan;42(2):e14. doi: 10.1093/nar/gkt995. Epub 2013 Oct 27.

47.

Age distribution for partial and radical nephrectomy: whose nephrons are being spared?

von Klot C, Herrmann TR, Wegener G, Kuczyk MA, Hupe MC, Akkoyun M, Peters I, Kramer MW, Merseburger AS.

Adv Ther. 2013 Oct;30(10):924-32. doi: 10.1007/s12325-013-0061-0. Epub 2013 Oct 24.

PMID:
24155056
48.

Age--an independent prognostic factor of clinical outcome in renal malignancies: results of a large study over two decades.

Hupe MC, Merseburger AS, Lokeshwar VB, Eggers H, Rott H, Wegener G, Abbas M, Kuczyk MA, Herrmann TR.

World J Urol. 2014 Feb;32(1):115-21. doi: 10.1007/s00345-013-1164-6. Epub 2013 Oct 2.

PMID:
24085371
49.

Resveratrol stimulates sphingosine-1-phosphate signaling of cathelicidin production.

Park K, Elias PM, Hupe M, Borkowski AW, Gallo RL, Shin KO, Lee YM, Holleran WM, Uchida Y.

J Invest Dermatol. 2013 Aug;133(8):1942-9. doi: 10.1038/jid.2013.133. Epub 2013 Mar 14.

50.

Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms.

Hou M, Sun R, Hupe M, Kim PL, Park K, Crumrine D, Lin TK, Santiago JL, Mauro TM, Elias PM, Man MQ.

Exp Dermatol. 2013 Mar;22(3):210-5. doi: 10.1111/exd.12102.

Supplemental Content

Support Center